Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)

Trial Profile

A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs Crizanlizumab (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Acronyms STAND
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 11 Dec 2018 New trial record
    • 01 Dec 2018 According to a Novartis media release, SOLACE-adults (A2202), SOLACE-kids (B2201), STAND (A2301), SUCCESSOR and SUSTAIN are a part of a "SENTRY program".
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top